Dexcom G7 CGMs contain a complex electronic assembly within a wearable package that stands up to the rigors of everyday ...
Investing.com - TD Cowen reiterated a Buy rating on DexCom Inc. (NASDAQ:DXCM) stock with an $84.00 price target. This aligns closely with InvestingPro’s Fair Value of $84.17, suggesting the stock ...
Investing.com - Evercore ISI upgraded DexCom (NASDAQ:DXCM) to Outperform from In Line and set a price target of $90.00, the firm said Monday. The upgrade reflects expectations for sustained revenue ...
Add Yahoo as a preferred source to see more of our stories on Google. Dexcom is poised to share new data on the benefits of its continuous glucose monitoring technology (CGM), which the company says ...
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026. Mr. Osterloh is a highly ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 47th Annual Raymond James Institutional Investors Conference on ...
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 47th Annual Raymond James Institutional Investors Conference on Monday, March 2, 2026. The live ...
Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...
DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...
DexCom reported revenue of $1.21 billion in the third quarter, up 22% year over year, with U.S. revenue growing by 21% and international revenue growing by 22%. Adjusted net income was $0.61 per share ...
Prefer Newsweek on Google to see more of our trusted coverage when you search. People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, ...
Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results